Dr. Reddy's Laboratories Limited: financial analysis
Ratios worked out from 10 fiscal years of Dr. Reddy's Laboratories Limited's statements, compared with 102 companies in Pharmaceutical.
Dr. Reddy's Laboratories Limited scorecard#
Passes 24 of the 30 checks that could be worked out: strongest in profitability (6 of 6), weakest in valuation (3 of 6). Fiscal year 2024; market cap of Nov 20, 2026.
Valuation3 of 6
- ✓P/E below its peers' median27.1×P/E 27.1× against Pharmaceutical's median of 39.4×.
- ✓Price to book below its peers' median3.0×Price to book 3.0× against Pharmaceutical's median of 3.2×.
- ✓Price to sales below its peers' median3.5×Price to sales 3.5× against Pharmaceutical's median of 3.5×.
- ✗Free cash flow yield above 5%1.8%Free cash flow is 1.8% of the market value.
- ✗Earnings yield above the 10-year Treasury yield3.7%Earnings yield 3.7% against the 10-year Treasury's 4.92% on 2026-11-20.
- ✗The price assumes slower growth than the last three years'13.9%The price assumes 13.9% a year for ten years; revenue grew 10.2% a year over the last three.
Growth5 of 6
- ✓Revenue grew in the newest year14.2%Revenue up 14.2% in fiscal 2024.
- ✓Revenue up more than 5% a year over three years10.2%10.2% a year over the three years to fiscal 2024.
- ✓Faster growth over three years than its peers' median10.2%10.2% a year against Pharmaceutical's median of 2.5% (65 companies).
- ✗Earnings per share grew in the newest year0.80 vs 0.81Diluted EPS 0.80 in fiscal 2024 against 0.81 the year before (report's currency).
- ✓Net income higher than five years earlier$669 M$669 M in fiscal 2024 against $275 M in 2019.
- ✓Revenue rose in at least four of the last five years5 of 5Revenue rose in 5 of the five years to fiscal 2024.
Profitability6 of 6
- ✓Profitable in the newest year$669 MNet income $669 M in fiscal 2024.
- ✓Profitable in each of the last five years5 of 5Profitable in 5 of the five years to fiscal 2024.
- ✓Operating margin above its peers' median22.1%22.1% against Pharmaceutical's median of 1.8% (74 companies).
- ✓Return on equity above 15%18.4%18.4% in fiscal 2024.
- ✓Return on invested capital above 10%17.7%17.7% in fiscal 2024.
- ✓Operating margin wider than three years earlier22.1%22.1% in fiscal 2024 against 13.7% in 2021.
Financial health6 of 6
- ✓Short-term assets cover short-term liabilities1.9×Current ratio 1.92 at the end of fiscal 2024.
- ✓Debt below equity0.0×Debt to equity 0.02 at the end of fiscal 2024.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $79 M at the end of fiscal 2024.
- ✓Operating income covers interest five times25.4×Operating income 25.4 times interest in fiscal 2024.
- ✓Cash from operations positive in each of the last three years3 of 3Positive in 3 of the three years to fiscal 2024.
- ✓Altman Z-score outside the distress zone6.46Z-score 6.46 (safe zone) for fiscal 2024.
Shareholder returns4 of 6
- ✓Pays a dividendYesPaid dividends in fiscal 2024.
- ✗Dividend per share raised five years in a row3 of 5Dividend per share raised in 3 of the five years to fiscal 2024.
- ✓Dividends under 75% of net income11.8%Dividends were 11.8% of net income in fiscal 2024.
- ✓Share count up no more than 2% in a year0.1%Diluted shares up 0.1% in fiscal 2024.
- ✗Dividends and buybacks above 3% of the market value0.8%Dividends and buybacks were 0.8% of the market value.
- ✓Free cash flow covers dividends and buybacks$224 MFree cash flow $224 M against $95 M paid out in fiscal 2024.
Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 20, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
What the 2024 statements show#
Each line is an observation with its numbers, not a judgement of the company.
Strengths
- Revenue has grown 6 years in a row.
- Free cash flow has been positive 10 years in a row.
- More cash than debt: net cash of $79 million.
Piotroski F-score
Nine yes/no tests of whether the company's finances improved in the year. One point each.
- Made a profityes
- Operations brought in cashyes
- Return on assets roseno
- Cash from operations exceeds profitno
- Long-term debt fell against assetsno
- Current ratio roseno
- No new shares issuedno
- Gross margin roseno
- Asset turnover roseno
Altman Z-score
A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.
| Part | Ratio | Weight | Points |
|---|---|---|---|
| Working capital to assets | 0.24 | × 1.2 | 0.29 |
| Retained earnings to assets | 0.64 | × 1.4 | 0.90 |
| Operating income to assets | 0.15 | × 3.3 | 0.49 |
| Market value to liabilities | 6.86 | × 0.6 | 4.12 |
| Revenue to assets | 0.67 | × 1 | 0.67 |
Where the return on equity comes from
The DuPont split: margin, times how hard the assets work, times how much of them is financed by others.
Profitability#
| Fiscal year | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 58.5% | 58.6% | 56.7% | 53.1% | 54.3% | 53.3% | 61% | |
| Operating margin | 22.1% | 24.3% | 23.2% | 13.8% | 12.8% | 1.8% | 88% | |
| Net margin | 17.4% | 20.0% | 18.3% | 11.0% | 9.1% | -1.5% | 91% | |
| Return on equity | 18.4% | 21.8% | 21.1% | 13.0% | 10.5% | -0.9% | 78% | |
| Return on assets | 12.8% | 15.7% | 14.4% | 8.4% | 6.9% | -1.3% | 88% | |
| Return on invested capital | 17.7% | 20.8% | 20.6% | 12.4% | 10.0% | 14.4% | 100% |
Growth#
| Fiscal year | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | 14.2% | 10.2% | 6.3% | 12.6% | 3.8% | 7.3% | 70% | |
| Revenue growth, 3 years a year | 10.2% | 9.7% | 7.5% | 9.4% | 5.1% | 2.5% | 72% | |
| Revenue growth, 5 years a year | 9.4% | 8.9% | 6.8% | 6.5% | 1.6% | 6.0% | 65% | |
| Net income growth | -0.6% | 20.0% | 77.3% | 36.2% | -15.5% | 14.3% | 33% | |
| Earnings per share growth | -0.6% | 19.7% | -64.6% | 36.2% | -15.6% | 12.4% | 36% |
Financial strength#
| Fiscal year | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Debt to equity | 0.02× | 0.02× | 0.01× | 0.03× | 0.04× | 0.66× | 94% | |
| Net debt | $-79 M | $-13 M | $-55 M | $-120 M | $-117 M | $188 M | 95% | |
| Net debt to EBITDA | -0.08× | -0.01× | -0.06× | -0.22× | -0.23× | 3.19× | 88% | |
| Interest cover | 25.40× | 39.58× | 40.01× | 30.76× | 25.03× | 1.11× | 96% | |
| Current ratio | 1.92× | 2.58× | 2.38× | 1.93× | 1.78× | 1.98× | 49% | |
| Equity share of assets | 67.6% | 72.4% | 71.8% | 65.1% | 65.2% | 47.3% | 75% |
Cash#
| Fiscal year | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Free cash flow | $224 M | $351 M | $592 M | $180 M | $350 M | $8 M | 70% | |
| Free cash flow margin | 5.8% | 10.4% | 19.3% | 6.3% | 13.7% | 6.0% | 49% | |
| Cash conversion | 82.1% | 81.6% | 130.6% | 119.3% | 207.1% | 136.7% | 21% | |
| Capital spending share of revenue | 8.5% | 5.9% | 4.6% | 6.8% | 5.1% | 2.6% | — |
Efficiency#
| Fiscal year | Trend | 2024 | 2023 | 2022 | 2021 | 2020 | Median of peers | Ahead of |
|---|---|---|---|---|---|---|---|---|
| Asset turnover | 0.74× | 0.79× | 0.79× | 0.77× | 0.76× | 0.55× | 69% |
How each figure is worked out#
- Gross margin
- Gross profit as a share of revenue.
- Operating margin
- Operating income as a share of revenue.
- Net margin
- Net income as a share of revenue.
- Return on equity
- Net income as a share of shareholders' equity (the average of the start and the end of the year). Not given when equity is negative.
- Return on assets
- Net income as a share of total assets (average of the year).
- Return on invested capital
- Operating income after tax, as a share of debt plus equity less cash (average of the year). The tax rate is the year's own: income tax over pre-tax income.
- Revenue growth
- Revenue against the year before.
- Revenue growth, 3 years a year
- The yearly rate that takes revenue of three years earlier to this year's.
- Revenue growth, 5 years a year
- The yearly rate that takes revenue of five years earlier to this year's.
- Net income growth
- Net income against the year before. Only when both years were profitable.
- Earnings per share growth
- Diluted earnings per share against the year before. Only when both were positive.
- Debt to equity
- Total debt divided by shareholders' equity. Not given when equity is negative.
- Net debt
- Total debt less cash. Negative means more cash than debt.
- Net debt to EBITDA
- Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
- Interest cover
- Operating income divided by the interest paid on debt.
- Current ratio
- Assets due within a year divided by liabilities due within a year.
- Equity share of assets
- Shareholders' equity as a share of total assets.
- Free cash flow
- Cash from operations less capital spending.
- Free cash flow margin
- Free cash flow as a share of revenue.
- Cash conversion
- Cash from operations as a share of net income. Only when the year was profitable.
- Capital spending share of revenue
- Capital spending as a share of revenue.
- Dividend yield
- Dividends paid in the fiscal year as a share of today's market value.
- Buyback yield
- Shares bought back in the fiscal year as a share of today's market value.
- Shareholder yield
- Dividends plus buybacks as a share of today's market value.
- Dividend payout
- Dividends paid as a share of net income. Only when the year was profitable.
- Change in share count
- Diluted shares against the year before. Negative: fewer shares.
- Asset turnover
- Revenue divided by total assets (average of the year).